54
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting

, &
Pages 391-395 | Published online: 14 Oct 2009

Abstract

Objective

To determine the effect of changing anticholinergic therapy in patients with COPD from ipratropium to tiotropium on pulmonary function.

Methods

We examined records of patients prescribed high-dose ipratropium, who were subsequently converted to tiotropium. Spirometric values were obtained within 2 days of the change in medication and after 56 to 224 days of the switch to tiotropium.

Results

15 subjects were documented to have filled a prescription for ipratropium-containing medications the month prior to the change. Medication compliance over the 6 months prior to the switch in these patients was 72% ± 31% (mean ± SD) for ipratropium compared to 87% ± 14% for tiotropium over the 6-month period after the switch (P = 0.1). FEV1 improved from 1.12 ± 0.39 L at baseline to 1.37 ± 0.49 L after the change to tiotropium (P = 0.01). FVC also improved from 2.45 ± 0.73 L at baseline to 2.72 ± 0.69 L after the change (P = 0.04). Maximal voluntary ventilation was also increased from 39.67 ± 10.7 L/min to 45.13 ± 15.8 L/min (P = 0.045).

Conclusions

We conclude that replacing high-dose ipratropium with tiotropium therapy significantly improves pulmonary function in a clinical setting.

Introduction

To date only smoking cessation or long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD) and resting hypoxemia have been shown to impact mortality in this disorder.Citation1,Citation2 However, some pharmacologic therapies impact a number of clinical parameters in patients with COPD.Citation2,Citation3 Currently there are 2 available inhaled anticholinergic medications, ipratropium and tiotropium, which improve air flow in patients with COPD. Tiotropium has a prolonged duration of action (>24 hours) compared to ipratropium.Citation3 A recent study has suggested tiotropium is cost-effective compared to ipratropium.Citation4 Tiotropium has been shown to improve 1) forced expiratory volume in 1 second (FEV1),Citation3 2) quality of life, and 3) exercise capacity and dyspnea compared to subjects treated with placebo or ipratropium.Citation5 Although these premarketing studies suggested an advantage of tiotropium over ipratropium in treatment of COPD patients there has not been any report of the effects of changing from ipratropium to tiotropium therapy in COPD patients followed in a general clinical setting.

Methods

Selection of subjects

Clinical records were reviewed of patients followed in a specialized clinic for COPD at the Birmingham VAMC who were previously treated with a regimen that contained high-dose ipratropium. This included use of the combination metered dose inhaler containing ipratropium (21 μg per puff), and albuterol (120 μg per puff), 2 puffs 4 times a day followed by ipratropium metered dose inhaler (MDI) (18 μg per puff) 4 inhalations 4 times a day. This resulted in a total of 456 μg of ipratropium inhaled each day. Patients were subsequently changed to tiotropium 18 μg capsule inhaled daily with albuterol MDI when necessary. Records of 24 subjects who had spirometry performed on the day of the change from ipratropium to tiotropium were further examined. Four of these subjects had evidence of a COPD exacerbation on the day of the switch and were not evaluated leaving 20 subjects for further evaluation. When only subjects were included who had refilled the prescription for ipratropium containing medications in the month prior to the switch, to minimize noncompliance as a complicating issue, a total of 15 remained for final evaluation.

Calculation of medication compliance

The records of prescription refills were examined for each of the 15 subjects and the number of prescription refills of ipratropium over the 6 months prior to, or tiotropium over the 6 months after the switch were determined. The percentage of compliance with the respective medication was calculated by the number of months the medication was refilled in those 6 months. If the subject refilled the medication 6 times (all prescriptions were 1 month supply at a time) compliance was calculated as 100%.

Pulmonary function testing

Spirometry was performed by American Thoracic Society guidelines.Citation6

Statistical analysis

Differences between means were determined by T test. A P value less then 0.05 was considered significant.

Results

Subjects and medication compliance

shows demographics of the 15 subjects in the study. Of the total number of subjects 15 patients had stage III, 2 subjects had stage IV and 4 subjects had stage II COPD as defined by GOLD.Citation7 All but 1 of the subjects had quit smoking. The average age for the 14 males and 1 female was 69.53 years. Compliance for anticholinergic use was 72% ± 31% (mean ± SD) for ipratropium 6 months prior to the switch compared to 87% ± 14% for tiotropium over the 6 month period after change in medication (P = 0.1). All patients were using the combination salmeterol/fluticasone inhaler Advair® during the month prior to the anticholinergic switch and through the entire period of the study.

Table 1 Characteristics of subjects at baseline

Pulmonary function testing

shows individual data for the FEV1 (A) and FVC (B) determined in the 15 subjects at baseline and after the change to tiotropium. FEV1 increased by an average of 155 mL (12.8%) (P = 0.01). Five of the 15 subjects showed an improvement of over 200 mL in FEV1. FVC also improved by an average of 273 mL (11.1%) P = 0.04. Maximal voluntary ventilation improved 5.46 L/min, an average of 13.8% (P = 0.045) (data not shown).

Figure 1 Effects of the switch from ipratropium anticholinergic therapy to tiotropium on FEV1 (A) and FVC (B).

Note: *P < 0.05 between the two treatments.
Figure 1 Effects of the switch from ipratropium anticholinergic therapy to tiotropium on FEV1 (A) and FVC (B).

Discussion

Our study suggests replacing high-dose inhaled ipratropium with tiotropium significantly improves FVC and FEV1. The effect on FEV1 suggests tiotropium has an advantage in improving airflow compared to high-dose ipratropium while effects of the change on FVC may be due to lessened air trapping.

A number of premarketing studies suggested tiotropium provides better bronchodilation compared to ipratropium administered 4 times a day and salmetrol administered twice a day, as evidenced by peak FEV1, trough FEV1 and area under the curve.Citation3 However, in all of these studies the comparator group was treated with a lower dose of ipratropium then was employed in the current study. Ikeda et al demonstrated that increasing doses of ipratropium up to 240 μg had progressively beneficial effects on exercise capacity and FEV1.Citation8 The dose of ipratropium used in our study at each single treatment time was 114 μg, less than the optimal dose demonstrated in that study but more than comparator ipratropium arms in premarket studies of tiotropium. However, in clinical practice use of a higher dose of ipratropium to achieve a dose of 160 μg at each dosing time would be problematic because of the large number of inhalations required per day and the cost of the number of inhalers required for that dose. To date, several more studies have demonstrated superior improvements in FEV1, FVC and FEV6 with tiotropium compared to placebo, ipratropium and long-acting β2-agonists.Citation9Citation13 Tiotropium was shown to improve FEV1 regardless of the presence or absence of short-term improvement in FEV1.Citation14 Moreover, improvements in inspiratory capacity and FEV1 with tiotropium in patients with hyperinflation are unrelated to small airway heterogeneity.Citation15 Tiotropium has also been shown to reduce dynamic hyperinflation resulting in improved exercise endurance.Citation3,Citation16,Citation17

Tiotropium has an excellent safety profile with dry mouth and urinary retention being the only major adverse events.Citation3,Citation13,Citation18Citation20 The incidence of dry mouth was slightly greater than that seen with ipratropium.Citation3 However, the effect was mild and did not lead to cessation of therapy. Serious adverse events occurred with the same frequency as in the control group.Citation3 A recently published meta-analysis of 17 randomized controlled trials raised concerns about an increased risk of cardiovascular death, myocardial infarction and stroke among COPD patients with use of inhaled anticholinergics (ipratropium or tiotropium).Citation21 However, the UPLIFT study did not demonstrate any such risks with long-term use of tiotropium.Citation22

Treatment with tiotropium is cost-effective compared to ipratropium.Citation4,Citation23 In a retrospective pooled analysis of long-acting bronchodilators, treatment with tiotropium was shown to save US$391 per year while gaining 13 quality-adjusted days compared with ipratropium.Citation23 Since hospitalizations due to COPD exacerbations account for up to 70% of the medical care costs for COPD patients, reduction in hospitalizations is a major reason for cost-effectiveness of treatment with tiotropium.Citation24,Citation25

Our study suggests that tiotropium 18 μg in a once-daily regimen improves airway flow rates when compared to a previous regimen of 456 μg of ipratropium per day. This, and previous studies, suggest an advantage of long-acting anticholinergic agent over short-acting ipratropium. Larger studies may be needed to determine the “real world” physiologic and economic effect of changing from ipratropium to tiotropum as anticholinergic therapy.

Disclosures

Dr Cooper has been on the speakers’ bureau for Boehringer Ingelheim, Pfizer and Glaxo Smith Kline pharmaceuticals in the past and has also performed clinical trials for each of this companies.

Dr Dransfield has been on the speakers’ bureau for Boehringer Ingelheim, Pf izer and Glaxo Smith Kline pharmaceuticals and has performed clinical trials for these companies.

References

  • SinDDMcAlisterFAManSFPAnthonisenNRContemporary management of chronic obstructive pulmonary diseaseJAMA20032902301231214600189
  • TashkinDPCooperCBThe role of long-acting bronchodilators in the management of stable COPDChest200412524925914718448
  • GrossNJTiotropium BromideChest20041261946195315596697
  • D’SouzaAOSmithMJMillerLAKavookjianJAn appraisal of pharmacoeconomic evidence of maintenance therapy for COPDChest20061291693170816778291
  • O’DonnellEDFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPDEur Respir J20042383284015218994
  • American Thoracic Society, European Respiratory SocietyATS/ERS task force: Standardization of lung function testingEur Resp J200526153161
  • PauwelsRABuistASCalverleyPMAGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO initiative for chronic obstructive lung disease (GOLD) workshop summaryAm J Respir Crit Care Med20011631256127611316667
  • IkedaANishimuraKKoyamaHTsukinoMMishimaMIzumiTDose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary diseaseThorax19965148538658369
  • HsuJYPerngRPLuJYDouble-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in TaiwanJ Formos Med Assoc200610570871416959618
  • ChankCKMaltaisFSigouinCA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic pulmonary diseaseCan Respir J20071446547218060091
  • CrinerGJSharafkhanehAPlayerREfficacy of tiotropium inhalation powder in African-American patients with chronic obstructive pulmonary diseaseCOPD20085354118259973
  • VoshaarTLapidusRMaleki-YazdiRA randomized study of tiotropium Respimat Soft mist inhaler vs ipratropium pMDI in COPDRespir Med2008102324117996436
  • BarrRGBourbeauJCamargoCATiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syt Rev20052 Art No.: CD00287610.1002/14651858.CD002876.pub2
  • TashkinDKestenSLong-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responsesChest20031231441144912740259
  • VerbanckSSchuermansDVinckenWSmall airways ventilation heterogeneity and hyperinflation in COPD: response to tiotropium bromideInt J Chron Obstruct Pulmon Dis2007262563418268937
  • CasaburiRKukafkaDCooperCBImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest200512780981715764761
  • MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest20051281168117816162703
  • BarrRGBourbeauJCamargoCATiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax200661852862
  • CasaburiRBriggsDDJrDonhueJFThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trialChest20001181294130211083677
  • KestenStevenMicheleJarWentworthCPooled clinical trial analysis of tiotropium safetyChest20061301695170317166984
  • SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysisJAMA20083001439145018812535
  • TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
  • ObaYCost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary diseaseMayo Clin Proc20078257558217493425
  • NiewoehnerDEThe impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary diseaseAm J Med2006119384516996898
  • RiceKLKunisakiKMNiewoehnerDERole of tiotropium in the treatment of COPDInt J Chron Obstruct Pulmon Dis200729510518044681